The global Treponema Pallidum (or Syphilis) Tests market is projected to reach $462m by 2028, growing at a Compound Annual Growth Rate (CAGR) of 2.99% between 2018 and 2028, according to GlobalData, a leading data and analytics company.
The company’s latest report, ‘Treponema Pallidum Tests’ reveals that North America and Asia Pacific will be the fastest growing regions with CAGRs of 3.28% and 3.44%, respectively, during the forecast period.
In many countries, the devices used for primary syphilis screening are changing and higher priced products such as chemiluminescence immunoassays and enzyme-linked immunosorbent assays are increasingly being employed. These newer devices are capable of high-throughput testing and enable institutions to reduce labor costs.
Alison Casey, Medical Devices Analyst at GlobalData comments, “A number of different factors influence growth of the Treponema Pallidum Tests market; these include testing of infection and suspected infection cases as well as screening of pregnant women, anonymous sperm donations, whole blood donations, and source plasma donations.”
Barriers to market growth include declining rates of live births and whole blood donations, which are occurring in many countries and geographical regions.
Casey concludes, “While the rising global incidence of syphilis is expected to drive growth of the Treponema Pallidum Tests market, this is just one factor that must contend with multiple other variables that work together to determine future trends of this highly complex in vitro diagnostics market”